Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.90K | 44.50K | 62.20K | 123.80K | 187.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.90K | 44.50K | 62.20K | 123.80K | 187.20K |
| Cost of Revenue | 135.30K | 175.50K | 215.90K | 226.70K | 239.40K |
| Gross Profit | -108.50K | -131.00K | -153.60K | -102.70K | -52.00K |
| SG&A Expenses | 373.10K | 959.00K | 1.55M | 2.00M | 2.46M |
| Depreciation & Amortization | 232.50K | 273.70K | 313.90K | 328.00K | 344.10K |
| Other Operating Expenses | 49.20K | 28.10K | 6.10K | 7.50K | 8.70K |
| Total Operating Expenses | 2.75M | 3.35M | 3.93M | 3.86M | 3.81M |
| Operating Income | -2.73M | -3.30M | -3.87M | -3.74M | -3.63M |
| Income Before Tax | -3.23M | -13.61M | -24.01M | -24.09M | -24.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.23 | -13.61 | -24.01 | -24.09 | -24.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 37.50K | 74.70K | 111.50K | 220.10K | 331.10K |
| Net Income | -3.20M | -13.53M | -23.90M | -23.87M | -23.85M |
| EBIT | -2.73M | -3.30M | -3.87M | -3.74M | -3.63M |
| EBITDA | -2.58M | -3.09M | -3.59M | -3.47M | -3.36M |
| EPS Basic | -0.28 | -1.19 | -2.11 | -2.11 | -2.11 |
| Normalized Basic EPS | -0.17 | -0.19 | -0.21 | -0.17 | -0.14 |
| EPS Diluted | -0.28 | -1.19 | -2.11 | -2.11 | -2.11 |
| Normalized Diluted EPS | -0.17 | -0.19 | -0.21 | -0.17 | -0.14 |
| Average Basic Shares Outstanding | 45.39M | 45.39M | 45.39M | 44.60M | 43.81M |
| Average Diluted Shares Outstanding | 45.39M | 45.39M | 45.39M | 44.60M | 43.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |